Top

Molecular Cancer

Published in:

Open Access 01-12-2016 | Research

RETRACTED ARTICLE: MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial–mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma

Authors: Zhenyue He, Jun Yi, Xiaolong Liu, Jing Chen, Siqi Han, Li Jin, Longbang Chen, Haizhu Song

Published in: Molecular Cancer | Issue 1/2016

Abstract

Background

Dysregulation of microRNAs (miRNAs) have been demonstrated to contribute to carcinogenesis. MiR-143-3p has been identified to function as a tumor suppressor in several tumors, but the role of miR-143-3p in esophageal squamous cell carcinoma (ESCC) has not been intensively investigated. Our aim was to evaluate the potential role of miR-143-3p in the progression of ESCC.

Methods

The expression levels of miR-143-3p and QKI-5 protein were measured in 80 resected ESCC tumor specimens and the clinicopathological significance of these levels determined. We also investigated the role of miR-143-3p in the regulation of QKI-5 expression in ESCC cell lines both in vivo and in vitro.

Results

MiR-143-3p levels were decreased in ESCC clinical samples and low expression of miR-143-3p was significantly associated with poor prognosis in ESCC patients. Ectopic expression of miR-143-3p suppressed proliferation and induced apoptosis in ESCC cells both in vivo and in vitro. Ectopic expression of miR-143-3p also reduced the metastatic potential of cells by selectively regulating epithelial–mesenchymal transition regulatory proteins. Furthermore, QKI-5 isoform was upregulated in ESCC tissues and was a direct target of miR-143-3p. Lastly, re-introduction of QKI-5 expression abrogated the inhibitory effects of miR-143-3p on ESCC cell proliferation and motility.

Conclusions

Our results demonstrate that miR-143-3p acts as a tumor-suppressor by targeting QKI-5 in ESCC, suggesting that miR-143-3p is a potential therapy for the treatment of ESCC.

Available only for authorised users

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.21208.CrossRefPubMed

Talukdar FR, Ghosh SK, Laskar RS, Mondal R. Epigenetic, genetic and environmental interactions in esophageal squamous cell carcinoma from northeast India. PLoS One. 2013;8(4):e60996. doi:10.1371/journal.pone.0060996.CrossRefPubMedPubMedCentral

Stiles BM, Nasar A, Mirza FA, Lee PC, Paul S, Port JL, et al. Worldwide Oesophageal cancer collaboration guidelines for lymphadenectomy predict survival following neoadjuvant therapy. Eur J Cardiothorac Surg. 2012;42(4):659–64. doi:10.1093/ejcts/ezs105.CrossRefPubMed

Chen Z, Ma T, Huang C, Hu T, Li J. The pivotal role of microRNA-155 in the control of cancer. J Cell Physiol. 2014;229(5):545–50. doi:10.1002/jcp.24492.CrossRefPubMed

Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26(4):462–9. doi:10.1038/nbt1392.CrossRefPubMed

Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61(1):33–42. doi:10.1136/gutjnl-2011-300178.CrossRefPubMed

Taniguchi K, Sugito N, Kumazaki M, Shinohara H, Yamada N, Nakagawa Y, et al. MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. Cancer Lett. 2015;363(1):17–27. doi:10.1016/j.canlet.2015.03.026.CrossRefPubMed

Xu YF, Mao YP, Li YQ, Ren XY, He QM, Tang XR, et al. MicroRNA-93 promotes cell growth and invasion in nasopharyngeal carcinoma by targeting disabled homolog-2. Cancer Lett. 2015;363(2):146–55. doi:10.1016/j.canlet.2015.04.006.CrossRefPubMed

Akanuma N, Hoshino I, Akutsu Y, Murakami K, Isozaki Y, Maruyama T, et al. MicroRNA-133a regulates the mRNAs of two invadopodia-related proteins, FSCN1 and MMP14, in esophageal cancer. Br J Cancer. 2014;110(1):189–98. doi:10.1038/bjc.2013.676.CrossRefPubMed

10.

Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, et al. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res. 2009;15(6):1915–22. doi:10.1158/1078-0432.CCR-08-2545.CrossRefPubMed

11.

Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, et al. miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010;127(12):2804–14. doi:10.1002/ijc.25284.CrossRefPubMed

12.

Hardy RJ, Loushin CL, Friedrich Jr VL, Chen Q, Ebersole TA, Lazzarini RA, et al. Neural cell type-specific expression of QKI proteins is altered in quakingviable mutant mice. J Neurosci. 1996;16(24):7941–9.CrossRef

13.

Pilotte J, Larocque D, Richard S. Nuclear translocation controlled by alternatively spliced isoforms inactivates the QUAKING apoptotic inducer. Genes Dev. 2001;15(7):845–58. doi:10.1101/gad.860301.CrossRefPubMedPubMedCentral

14.

Bockbrader K, Feng Y. Essential function, sophisticated regulation and pathological impact of the selective RNA-binding protein QKI in CNS myelin development. Future Neurol. 2008;3(6):655–68. doi:10.2217/14796708.3.6.655.CrossRefPubMedPubMedCentral

15.

Galarneau A, Richard S. Target RNA motif and target mRNAs of the Quaking STAR protein. Nat Struct Mol Biol. 2005;12(8):691–8. doi:10.1038/nsmb963.CrossRefPubMed

16.

Zhao Y, Zhang G, Wei M, Lu X, Fu H, Feng F, et al. The tumor suppressing effects of QKI-5 in prostate cancer: a novel diagnostic and prognostic protein. Cancer Biol Ther. 2014;15(1):108–18. doi:10.4161/cbt.26722.CrossRefPubMed

17.

Yang G, Fu H, Zhang J, Lu X, Yu F, Jin L, et al. RNA-binding protein quaking, a critical regulator of colon epithelial differentiation and a suppressor of colon cancer. Gastroenterology. 2010;138(1):231–40 e1-5. doi:10.1053/j.gastro.2009.08.001.CrossRefPubMed

18.

van der Veer EP, de Bruin RG, Kraaijeveld AO, de Vries MR, Bot I, Pera T, et al. Quaking, an RNA-binding protein, is a critical regulator of vascular smooth muscle cell phenotype. Circ Res. 2013;113(9):1065–75. doi:10.1161/CIRCRESAHA.113.301302.CrossRefPubMed

19.

Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–96. doi:10.1038/nrm3758.CrossRefPubMedPubMedCentral

20.

Lin T, Dong W, Huang J, Pan Q, Fan X, Zhang C, et al. MicroRNA-143 as a tumor suppressor for bladder cancer. J Urol. 2009;181(3):1372–80. doi:10.1016/j.juro.2008.10.149.CrossRefPubMed

21.

Liu L, Yu X, Guo X, Tian Z, Su M, Long Y, et al. miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Rep. 2012;5(3):753–60. doi:10.3892/mmr.2011.696.CrossRefPubMed

22.

Wu XL, Cheng B, Li PY, Huang HJ, Zhao Q, Dan ZL, et al. MicroRNA-143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2. World J Gastroenterol. 2013;19(43):7758–65. doi:10.3748/wjg.v19.i43.7758.CrossRefPubMedPubMedCentral

23.

Hall MP, Nagel RJ, Fagg WS, Shiue L, Cline MS, Perriman RJ, et al. Quaking and PTB control overlapping splicing regulatory networks during muscle cell differentiation. RNA. 2013;19(5):627–38. doi:10.1261/rna.038422.113.CrossRefPubMedPubMedCentral

24.

Larocque D, Galarneau A, Liu HN, Scott M, Almazan G, Richard S. Protection of p27(Kip1) mRNA by quaking RNA binding proteins promotes oligodendrocyte differentiation. Nat Neurosci. 2005;8(1):27–33. doi:10.1038/nn1359.CrossRefPubMed

25.

Saccomanno L, Loushin C, Jan E, Punkay E, Artzt K, Goodwin EB. The STAR protein QKI-6 is a translational repressor. Proc Natl Acad Sci U S A. 1999;96(22):12605–10.CrossRef

26.

He B, Gao SQ, Huang LD, Huang YH, Zhang QY, Zhou MT, et al. MicroRNA-155 promotes the proliferation and invasion abilities of colon cancer cells by targeting quaking. Mol Med Rep. 2015;11(3):2355–9. doi:10.3892/mmr.2014.2994.CrossRefPubMed

27.

Lu W, Feng F, Xu J, Lu X, Wang S, Wang L, et al. QKI impairs self-renewal and tumorigenicity of oral cancer cells via repression of SOX2. Cancer Biol Ther. 2014;15(9):1174–84. doi:10.4161/cbt.29502.CrossRefPubMedPubMedCentral

28.

Tili E, Chiabai M, Palmieri D, Brown M, Cui R, Fernandes C, et al. Quaking and miR-155 interactions in inflammation and leukemogenesis. Oncotarget. 2015;6(28):24599–610.CrossRef

29.

Chenard CA, Richard S. New implications for the QUAKING RNA binding protein in human disease. J Neurosci Res. 2008;86(2):233–42. doi:10.1002/jnr.21485.CrossRefPubMed

30.

Chen AJ, Paik JH, Zhang H, Shukla SA, Mortensen R, Hu J, et al. STAR RNA-binding protein quaking suppresses cancer via stabilization of specific miRNA. Genes Dev. 2012;26(13):1459–72. doi:10.1101/gad.189001.112.CrossRefPubMedPubMedCentral

31.

Bian Y, Wang L, Lu H, Yang G, Zhang Z, Fu H, et al. Downregulation of tumor suppressor QKI in gastric cancer and its implication in cancer prognosis. Biochem Biophys Res Commun. 2012;422(1):187–93. doi:10.1016/j.bbrc.2012.04.138.CrossRefPubMed

32.

Fu X, Feng Y. QKI-5 suppresses cyclin D1 expression and proliferation of oral squamous cell carcinoma cells via MAPK signalling pathway. Int J Oral Maxillofac Surg. 2015;44(5):562–7. doi:10.1016/j.ijom.2014.10.001.CrossRefPubMed

33.

Zong FY, Fu X, Wei WJ, Luo YG, Heiner M, Cao LJ, et al. The RNA-binding protein QKI suppresses cancer-associated aberrant splicing. PLoS Genet. 2014;10(4):e1004289. doi:10.1371/journal.pgen.1004289.CrossRefPubMedPubMedCentral

Title: RETRACTED ARTICLE: MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial–mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma
Authors: Zhenyue He
Jun Yi
Xiaolong Liu
Jing Chen
Siqi Han
Li Jin
Longbang Chen
Haizhu Song
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2016
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/s12943-016-0533-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

ErbB2 and p38γ MAPK mediate alcohol-induced increase in breast cancer stem cells and metastasis

Estrogen receptor α in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment

A bioavailable cathepsin S nitrile inhibitor abrogates tumor development

MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression

Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model

Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer